TECH · 10-Q/A · 2026Q3

BIO-TECHNE Corp

Filed 2026-11-12 · Healthcare · View original filing on EDGAR

Everything TECH's SEC filings said, ranked

Ranked Events

• Pending Merger with MerckImportance 71 · Surprise 60
  In June 2026, Bio-Techne entered into a merger agreement with Merck KGaA, Darmstadt, Germany, under which Merck’s wholly owned subsidiary will merge into Bio-Techne, which will survive as a wholly owned subsidiary.…
• Balance Sheet and LiquidityImportance 69 · Surprise 64
  Cash and cash equivalents were $350.0 million at September 30, 2026, up from $264.7 million at June 30, 2026. The Company had $800.0 million available under its revolving line of credit, which matures August 31, 2027,…
• Capital Expenditure ProgramImportance 59 · Surprise 32
  Capital expenditures for fixed assets were $5.9 million in the first quarter of fiscal 2027, compared with $5.4 million in the first quarter of fiscal 2026. The Company expected approximately $28 million of additional…
• Operating Margin DriversImportance 59 · Surprise 48
  Gross margin increased 4.5% to $196.6 million, but gross margin as a share of revenue edged down to 65.6% from 65.7%. Operating income declined 23.2% to $36.6 million from $47.7 million, reducing operating margin to…
• Acquisition / Partnership / DivestitureImportance 58 · Surprise 42
  In the fourth quarter of fiscal 2025, Bio-Techne classified assets and liabilities associated with its Exosome Diagnostics business as held for sale, including $4.5 million of allocated goodwill. A fiscal 2025…
• Geographic Revenue PerformanceImportance 56 · Surprise 40
  United States revenue decreased 1.7% year over year to $152.7 million. EMEA excluding the United Kingdom grew 13.5% to $73.9 million, while United Kingdom revenue rose 4.0% to $13.7 million. APAC excluding Greater…
• Operating Expense TrendsImportance 54 · Surprise 40
  Selling, general and administrative expense increased 15.0% year over year to $133.7 million from $116.2 million. Research and development expense increased 8.7% to $26.3 million from $24.2 million, while total…
• Market Demand TrendsImportance 49 · Surprise 32
  Bio-Techne develops and sells biotechnology reagents, instruments, and services for research and clinical diagnostic markets worldwide. In the quarter ended September 30, 2026, consolidated organic revenue increased 7%…
• Revenue Performance and MixImportance 49 · Surprise 32
  Quarterly net sales increased 4.6% year over year to $299.7 million from $286.6 million. Consumables revenue rose 2.4% to $237.3 million, instrument revenue rose 16.8% to $25.5 million, and service revenue declined…
• Restructuring ChargesImportance 33 · Surprise 42
  Fiscal 2026 restructuring actions focused on streamlining brand architecture and realigning brand-support functions, including operations and personnel; the Company expects related costs through fiscal 2027. Costs…
• DividendsImportance 18 · Surprise 14
  Bio-Techne paid $12.6 million in cash dividends to common shareholders during the first quarter of fiscal 2027. The comparable payment in the first quarter of fiscal 2026 was $12.4 million. Management included cash…
• Income Tax Rate ChangesImportance 18 · Surprise 14
  The effective income tax rate was 18.4% for the quarter ended September 30, 2026, compared with 20.4% in the prior-year quarter, reflecting the mix of net income and timing of discrete items. The forecasted tax rate…

Revenue by Product (in thousands)

Revenue by Geography (in thousands)